Myocarditis;Myokarditis

Deutsches Arzteblatt International

Volumn 109, Issue 20, 2012, Pages

  Kühl, Uwe ^a   Schultheiss, Heinz Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIAC PATIENT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; DISEASE COURSE; HEART FAILURE; HEART MUSCLE; HEART MUSCLE BIOPSY; HEART MUSCLE INJURY; HUMAN; MYOCARDITIS; PATHOPHYSIOLOGY; PROGNOSIS; STANDARDIZATION;

EID: 84903362131     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2012.0361     Document Type: Article

References (32)

1. Schultheiss HP, Kuehl U, Cooper LT: The management of myocarditis. Eur Heart J 2011; 32: 2616-65.
2. D'Ambrosio A, Patti G, Manzoli A, et al.: The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001; 85: 499-504.
3. Magnani JW, Dec GW: Myocarditis: current trends in diagnosis and treatment. Circulation 2006; 113: 876-90.
4. Cooper LT, Baughman KL, Feldman AM, et al.: The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 2007; 28: 3076-93.
5. Baboonian C, Treasure T: Meta-analysis of the association of enteroviruses with human heart disease. Heart 1997; 78: 539-43.
6. Liu PP, Schultheiss HP: Myocarditis. In: Baunwald (ed.):, Heart Disease. 8 ed. Philadelphia: W B Saunders co; 2008: 1775-92.
7. McCarthy RE, Boehmer JP, Hruban RH, et al.: Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342: 690-5.
8. Cooper LT Jr., Berry GJ, Shabetai R: Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 1997; 336: 1860-6.
9. Why HJ, Meany BT, Richardson PJ, et al.: Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994; 89: 2582-9.
10. Mason JW, O'Connell JB, Herskowitz A, et al.: A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333: 269-75.
11. Magnani JW, Suk Danik HJ, Dec GW, DiSalvo TG: Survival in biopsyproven myocarditis: A long-term retrospective analysis of the histopathological, clinical, and hemodynamic predictors. Am Heart J 2006; 151: 463-70.
12. Frustaci A, Chimenti C, Calabrese F, et al.: Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003; 107: 857-63.
13. Caforio AL, Calabrese F, Angelini A, et al.: A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007; 28: 1326-33.
14. Yilmaz A, Kindermann I, Kindermann M, et al.: Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 2010; 122: 900-9.
15. Kuhl U, Lassner D, Pauschinger M, et al.: Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol 2008; 80: 1243-51.
16. Kindermann I, Kindermann M, Kandolf R, et al.: Predictors of out -come in patients with suspected myocarditis. Circulation 2008; 118: 639-48.
17. Hunt SA, Abraham WT, Chin MH, et al.: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-e479.
18. Kühl U, Strauer BE, Schultheiss HP: Methylprednisolone in chronic myocarditis. Postgrad Med J 1994; 70: 35-42.
19. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al.: Ran -domized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001; 104: 39-45.
20. Stanton C, Mookadam F, Cha S, et al.: Greater symptom duration predicts response to immunomodulatory therapy in dilated cardiomyopathy. Int J Cardiol 2008; 128: 38-41.
21. Cooper L, Hare JM, Tazelaar HD, et al.: Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008; 102: 1535-9.
22. Frustaci A, Russo MA, Chimenti C: Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009.
23. Kuhl U, Pauschinger M, Seeberg B, et al.: Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112: 1965-70.
24. Kuhl U, Pauschinger M, Schwimmbeck PL, et al.: Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107: 2793-8.
25. Schultheiss HP, Piper C, Sowade K, et al.: The effect of subcutaneous treatment with interferon-beta-1b over 24 weeks on safety,virus elimination and clinical outcome in patients with chronic viral cardiomyopathy. Circulation 2008: Abstract 3322.
26. Aoyama N, Izumi T, Hiramori K, et al.: National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). Circ J 2002; 66: 133-44.
27. Mason JW: Techniques for right and left ventrikulär endomyocardial biopsy. Am J Cardiol 1978; 41: 887-94.
28. Brehm M, Rellecke P, Strauer BE: Inflammatory cardiac diseases by primary extracardial diseases. Internist 2008; 49: 27-33.
29. Aretz HT: Myocarditis: the Dallas criteria. Hum Pathol 1987; 18: 619-24.
30. e5. Kuhl U, Noutsias M, Seeberg B, Schultheiss HP: Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart 1996; 75: 295-300.
31. Noutsias M, Pauschinger M, Ostermann K, et al.: Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. Med Sci Monit 2002; 8: MT59-71.
32. Okura Y, Dec GW, Hare JM, et al: A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 2003; 41: 322-9.